

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01345)

VOLUNTARY ANNOUNCEMENT AND BUSINESS UPDATE PRE-EUA PROCESS OF CERTAIN NOVEL CORONAVIRUS TEST KITS

China Pioneer Pharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Food and Drug Administration of the United States (“**FDA**”) has recently commenced with the Pre-Emergency Use Authorization (the “**Pre-EUA**”) process on the Novel Coronavirus (SARS-CoV-2) IgG/IgM Combined Antibody Test Kit (Fluorescence Immunochromatography Method) (the “**Test Kits**”).

The Test Kits are the products of Shenzhen Microprofit Biotech Co., Ltd. (“**Shenzhen Microprofit**”), a company incorporated in the People’s Republic of China and a third party which is and whose shareholders are independent of the Company and of its connected persons (with the meanings ascribed thereto by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited). The Group acts as the exclusive agent in the United States for a term of 10 years from 2020 of various Novel Coronavirus (SARS-CoV-2) test kits of Shenzhen Microprofit currently in development.

The Pre-EUA process allows FDA scientific and technical subject matter experts to begin a review of information and assist in the development of conditions of authorization, fact sheets, and other documentation that would be needed for an Emergency Use Authorization (“**EUA**”) in advance of an emergency and helps to facilitate complete EUA requests during a current emergency declaration. An EUA allows FDA to authorize the use of an unapproved medical countermeasures, in anticipation of a potential emergency or during an actual emergency.

The Test Kits are subject to the Pre-EUA process and requirements and there is no assurance for success in the Pre-EUA process and/or the subsequent EUA. There are inherent uncertainties in the prospects of the Test Kits, their commercialization (if at all) and the Group's agency business thereof. Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
China Pioneer Pharma Holdings Limited
LI Xinzhou
Chairman

Hong Kong, 4 June 2020

As at the date of this announcement, the directors of the Company are Mr. LI Xinzhou, Mr. LUO Chunyi and Mr. LUK Chi Shing as executive directors, Mr. WU Mijia and Mr. HUI Lap Keung as non-executive directors and Mr. ZHANG Hong, Mr. XIAO Guoguang and Mr. WONG Chi Hung, Stanley as independent non-executive directors.